Wednesday, 21 February, 2018

Juno Therapeutics Inc (JUNO) CEO Hans Edgar Bishop Sells 270250 Shares

CAR-T blood cancer cell therapy Juno Therapeutics, Inc. (JUNO): What's the Story?
Nellie Chapman | 23 January, 2018, 00:57

Citigroup cut shares of Juno Therapeutics (NASDAQ:JUNO) from a buy rating to a neutral rating in a research report sent to investors on Wednesday morning, MarketBeat.com reports. Zacks Investment Research downgraded shares of Juno Therapeutics from a hold rating to a sell rating in a report on Wednesday. Trading volume for Juno Therapeutics Inc. was 8.44 Million in its previous trading session. The stock tapped a 52-week high of US$3.25 while the mean 12-month price target for the shares is US$3.67. Separately, on January 18, Maxim's Jason McCarthy assigned a Buy rating to the stock and has a price target of $98. "Ultimately, through all this investigation into the company's performance the analyst decides whether their stock is a "buy", sell" or hold". The company now has an average rating of "Hold" and an average target price of $47.26. Capital International Sarl who had been investing in Netease Inc Adr for a number of months, seems to be bullish on the $42.73 billion market cap company. JUNO's latest closing price was 82.13% away from the average price of 200 days while it maintained a distance of 28.90% from the 50 Day Moving Average and 37.05% away compared to its SMA 20. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77. The stock of Juno Therapeutics, Inc.

The Wall Street Journal reported last week the two companies were in deal talks. The firm had revenue of $44.80 million during the quarter, compared to analysts' expectations of $18.12 million. According to their observations and findings, the stock could provide a high EPS of $-0.59/share and a low EPS of $-1.59/share. This downside isn't anything new for Celgene shares, which have shed roughly 26% in the past six months, and recent resistance forming at the stock's 60-day trendline. On a consensus basis, analysts have given a recommendation of 2.30 on company shares. Also, Director Richard Klausner sold 36,000 shares of the stock in a transaction on Thursday, December 21st.

Celgene already owns approximately a stake of around 9.7% in Juno. The disclosure for this sale can be found here.

David Nierengarten, head of health-care equity research at Wedbush, told CNBC, "Celgene has a big revenue hole to fill over the next few years" and Juno's treatment could potentially "fill that gap". The stock increased 1.04% or $3.36 during the last trading session, reaching $325.55. It also increased its holding in Omeros Corp (NASDAQ:OMER) by 400,000 shares in the quarter, for a total of 1.70M shares, and has risen its stake in Mersana Therapeutics. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company's stock valued at $128,357,000 after purchasing an additional 110,503 shares during the last quarter. Finally, Capital World Investors boosted its position in shares of Juno Therapeutics by 13.8% during the 2nd quarter. SG Americas Securities LLC now owns 15,254 shares of the biopharmaceutical company's stock worth $684,000 after purchasing an additional 1,328 shares during the last quarter. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders.